Trials / Completed
CompletedNCT06628791
BK329 and Body Fat Reduction
Effects of Oral Intake of BK329 on Body Fat Reduction in Adults With Overweight or Obesity: a Randomized, Double-blind, Placebo-controlled Clinical Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Pusan National University Yangsan Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This clinical trial aims to determine whether BK329 reduces body fat in adults with overweight or obesity and to assess its safety. The main questions are: * Does BK329 reduce body fat in participants? * What side effects occur when participants take BK329?
Detailed description
Researchers will compare BK329 to a placebo to evaluate its effectiveness in reducing body fat. Participants will: * Take BK329 or a placebo daily for 12 weeks. * Visit the clinic every six weeks for checkups and tests.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | BK329 | Lactococcus lactics. subsp. lactis CAB701(KCCM13360P) 400 mg/day for 12 weeks |
| DIETARY_SUPPLEMENT | Placebo | Placebo 400 mg/day for 12 weeks |
Timeline
- Start date
- 2024-01-26
- Primary completion
- 2024-07-08
- Completion
- 2024-12-31
- First posted
- 2024-10-08
- Last updated
- 2026-01-06
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06628791. Inclusion in this directory is not an endorsement.